Chugai Pharmaceutical : Notice of Changes in Representative Directors and Directors
February 03, 2022 at 08:09 am
Share
February 3, 2022
Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number:
4519 (1st Section of Tokyo Stock Exchange)
Head office:
1-1,Nihonbashi-Muromachi2-Chome,Chuo-ku, Tokyo
President & CEO:
Osamu Okuda
Inquiries to:
Toshiya Sasai
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554
Notice of Changes in Representative Directors and Directors
Chugai Pharmaceutical Co., Ltd. (the "Company") announces changes in Representative Directors and Directors with the resolution of the Board of Directors Meeting held on February 3, 2022, as described below. The changes will be formalized after the Annual General Meeting of Shareholders and the Board of Directors Meeting scheduled on March 29, 2022.
1. Change in Representative Directors
(1) Reason for Change
Since the conclusion of the strategic alliance agreement with Roche in 2001, the Company has been working diligently to establish a unique business model. In order to achieve sustainable growth and development of the Chugai group and further enhance the corporate value through promoting our growth strategy "TOP I 2030" under a new management structure in 2022, Tatsuro Kosaka, Representative Director and Chairman, and Motoo Ueno, Representative Director and Deputy Chairman will retire, and Executive Vice Presidents, Hisafumi Yamada and Toshiaki Itagaki will be appointed as Directors.
(2) Retiring Representative Directors
Name
Current Title
Tatsuro Kosaka
Representative Director, Chairman
Motoo Ueno
Representative Director, Deputy Chairman
Tatsuro Kosaka and Motoo Ueno are expected to be appointed as Senior Advisors.
Osamu Okuda is expected to be appointed as Chairman of the Board of Directors.
Effective Date March 29, 2022
2. Change in Directors
Newly Appointed Directors
Name
New Title
Current Title
Director, Executive Vice President
Executive Vice President
Supervisory responsibility for Project &
Supervisory responsibility for Project &
Hisafumi Yamada
Lifecycle Management (R&D), Research,
Lifecycle Management (R&D), Research,
Translational Research, Clinical
and Translational Research
Development, and Pharmaceutical
Technology
Director, Executive Vice President
Executive Vice President
Chief Financial Officer (CFO)
Chief Financial Officer (CFO)
Toshiaki Itagaki
Supervisory responsibility for Finance &
Supervisory responsibility for Finance &
Accounting, Corporate Communication, and
Accounting, Corporate Communication,
Purchasing
Purchasing, and Digital Transformation
Head of Finance Supervisory Div.
Head of Finance Supervisory Div.
Effective Date March 29, 2022
###
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 03 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 February 2022 08:08:07 UTC.
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%).
Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).